Clinical Trial Update: A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Fluzoparib in combination with QL1101 as maintenance therapy after response to front-line platinum in advanced ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Fluzoparib (fluzoparib)
• QL1101 (bevacizumab biosimilar)

Snippet

Sponsor: Yongpeng Wang | Conditions: Ovarian Cancer | Phase 2 | Status: UNKNOWN